Drug intelligence / Profile preview

therapeutic HBV vaccine

Development stage: Unknown
Lead developer: Chongqing Jiachen Biotechnology
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

The therapeutic HBV vaccine is a mimogen-based, peptide vaccine containing εPA-44, developed by Chongqing Jiachen Biotechnology Ltd. It is designed to treat chronic Hepatitis B (CHB) patients, particularly those who are HBeAg positive. The vaccine aims to stimulate the body's immune system to overcome immune tolerance to the Hepatitis B virus (HBV) by inducing specific T-cell and B-cell responses against HBV antigens, thereby promoting viral clearance.

Other names: Mimogen-based therapeutic HBV vaccine

Targets

HBV antigens (Hepatitis B virus antigens)

Beyond the preview

Go deeper on therapeutic HBV vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on therapeutic HBV vaccine.

Explore the full profile